News|Articles|September 16, 2013

AMRI Announces Executive Leadership Changes

Author(s)Pharmaceutical Technology Editors

AMRI reported that Thomas E. D'Ambra, PhD. will retire as president and CEO.

Albany Molecular Research (AMRI), a provider of contract discovery, development and manufacturing services, has announced that Thomas E. D’Ambra, PhD, will retire as president and CEO, effective Dec. 31, 2013. D’Ambra will be named the company’s nonexecutive chairman of the board of directors on the same date.

D’Ambra will be succeeded as president and CEO by William S. Marth, currently nonexecutive chairman of the AMRI Board, effective Jan. 1, 2014. Marth will remain a member of the company’s board of directors.

Source: Albany Molecular Research

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.